Gilead Sciences has argued that its hep C blockbuster Sovaldi will save healthcare payers money by preventing transplants for patients who develop cancer. But now the U.S. drugmaker has run into the Germany's IQWiG, the toughest among Europe's drug price watchdogs, and it says the evidence for that claim is unclear.
written on 02.05.2014
Germany says it is unclear whether Gilead's Sovaldi prevents liver cancer
